title: Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom.
abstract: The introduction of routine infant immunization with Haemophilus influenzae type b (Hib) conjugate vaccines in the United Kingdom in 1992 led to a significant reduction in invasive disease due to this organism. Subsequently, between 1999 and 2003 there was an increase in the number of immunized children with Hib infection. We investigated whether the rise in cases was related to changes in anti-polyribosylribitol phosphate (PRP) antibody concentration or avidity. Using stored sera, we analyzed temporal changes in antibody levels among 3- to 5-year-old children immunized between 1991 and 2000. Anti-PRP antibody concentrations were higher in 3- to 5-year-olds who received infant immunization in 1991 than those in subsequent years. This difference may be related to changes in either the mode of administration of Hib conjugate vaccines or the rates of Hib nasopharyngeal carriage. This study emphasizes the factors affecting anti-PRP antibody concentration following immunization with conjugate vaccines and the importance of these in long-term protection from invasive disease.
authors.affiliation: Oxford Vaccine Group, Oxford University Department of Paediatrics, Oxford, United Kingdom. dominic.kelly@paediatrics.ox.ac.uk
authors.forename: Dominic F
authors.initials: DF
authors.lastname: Kelly
authors.forename: E Richard
authors.initials: ER
authors.lastname: Moxon
authors.forename: Ly-Mee
authors.initials: LM
authors.lastname: Yu
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Pollard
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology*; D016667:Bacterial Capsules / Q000276:immunology; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D018073:Haemophilus Vaccines / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D007223:Infant; D011134:Polysaccharides / Q000276:immunology*; D006113:United Kingdom
chemical_list: D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011134:Polysaccharides; C008984:polyribitol phosphate
references.citation: J Clin Invest. 1972 Jan;51(1):31-8
references.pmid: 4536614
references.citation: J Infect Dis. 1998 Apr;177(4):1112-5
references.pmid: 9534995
references.citation: Vaccine. 2000 Sep 15;19(2-3):367-75
references.pmid: 10930692
references.citation: Pediatr Infect Dis J. 1993 Jun;12(6):478-84
references.pmid: 8345980
references.citation: Commun Dis Public Health. 2003 Apr;6(1):55-8
references.pmid: 12736974
references.citation: N Engl J Med. 2006 Apr 6;354(14):1522-4
references.pmid: 16598050
references.citation: Expert Rev Vaccines. 2008 Feb;7(1):97-115
references.pmid: 18251697
references.citation: Epidemiol Infect. 2007 Jul;135(5):861-7
references.pmid: 17092395
references.citation: Pediatr Infect Dis J. 1991 Oct;10(10):764-71
references.pmid: 1945579
references.citation: Pediatrics. 1993 Dec;92(6):827-32
references.pmid: 8233745
references.citation: Vaccine. 1998 May-Jun;16(9-10):921-7
references.pmid: 9682338
references.citation: CMAJ. 1993 Oct 15;149(8):1105-12
references.pmid: 8221449
references.citation: Immunology. 2004 Oct;113(2):163-74
references.pmid: 15379976
references.citation: Epidemiol Infect. 2004 Aug;132(4):765-7
references.pmid: 15310180
references.citation: J Infect Dis. 1995 Jan;171(1):93-8
references.pmid: 7798687
references.citation: Vaccine. 2004 Jan 2;22(3-4):378-82
references.pmid: 14670319
references.citation: JAMA. 2005 Apr 13;293(14):1751-8
references.pmid: 15827314
references.citation: Pediatr Infect Dis J. 1994 May;13(5):348-55
references.pmid: 8072815
references.citation: Lancet. 2003 May 3;361(9368):1523-4
references.pmid: 12737867
references.citation: Infect Immun. 1998 May;66(5):2093-8
references.pmid: 9573094
references.citation: JAMA. 2000 Nov 8;284(18):2334-40
references.pmid: 11066183
references.citation: Lancet. 1999 Dec 11;354(9195):2063-8
references.pmid: 10636384
references.citation: Clin Infect Dis. 2008 Jan 15;46(2):186-92
references.pmid: 18171249
references.citation: J Pediatr. 1999 Feb;134(2):253-4
references.pmid: 9931552
references.citation: Pediatr Infect Dis J. 1998 Sep;17(9 Suppl):S117-22
references.pmid: 9781743
references.citation: Pediatr Infect Dis J. 1993 Aug;12(8):638-43
references.pmid: 8414775
references.citation: BMJ. 1992 Aug 29;305(6852):485-6
references.pmid: 1392989
references.citation: Emerg Infect Dis. 1996 Jul-Sep;2(3):176-82
references.pmid: 8903227
references.citation: JAMA. 1992 Mar 18;267(11):1489-94
references.pmid: 1538539
references.citation: Vaccine. 1997 Feb;15(2):149-54
references.pmid: 9066031
references.citation: Arch Dis Child. 1992 Apr;67(4):475-8
references.pmid: 1580674
references.citation: Arch Dis Child. 2003 May;88(5):379-83
references.pmid: 12716702
references.citation: BMJ. 2004 Sep 18;329(7467):655-8
references.pmid: 15374916
references.citation: Vaccine. 1995 Nov;13(16):1547-50
references.pmid: 8578840
references.citation: Pediatrics. 1995 Apr;95(4):522-7
references.pmid: 7700752
references.citation: Acta Paediatr. 2003 May;92(5):541-5
references.pmid: 12839281
references.citation: Clin Infect Dis. 2002 Jan 15;34(2):191-7
references.pmid: 11740707
references.citation: Lab Invest. 1979 Jun;40(6):678-85
references.pmid: 312973
references.citation: J Med Microbiol. 2006 Jul;55(Pt 7):887-896
references.pmid: 16772416
references.citation: Lancet. 2003 May 3;361(9368):1521-3
references.pmid: 12737866
references.citation: Arch Dis Child. 2007 Jan;92(1):11-6
references.pmid: 16670121
references.citation: Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S278-87
references.pmid: 11709760